Less than two weeks after announcing the promotion of Mike Motion from Chief Commercial Officer to Chief Operating Officer, inhaler monitoring company Adherium has named Motion as its new CEO, replacing interim CEO Jeremy Curnock Cook. The company also announced that it has hired former Menarini Asia-Pacific CFO Anne Bell as Chief Financial Officer.
In November 2019, Adherium named Peter Stratford as its new CEO, replacing then interim CEO Curnock Cook. Adherium had previously named Arik Anderson CEO in June 2017, replacing founder Garth Sutherland. Anderson remained as CEO until December 2018, when the company announced that it would reorganize.
Newly appointed Chairman of the Board James Ward Lilley said, “I am pleased to announce Mike’s promotion to the role of Chief Executive and welcome him to the Board as a Director. Having worked closely with Mike over the last few months I am confident he can effectively lead the Adherium business. Mike has played a key role since joining Adherium in November including the re-financing activity alongside the refresh of strategy, business model, technology development plan and organization. Mike has also brought his network, energy and focus to the acceleration of new partnering activities particularly in the US.”
Lilley added, “I am also pleased that Anne has accepted the offer to join the business as CFO reporting to Mike based in Melbourne. Anne has a very strong background in finance, commerce and business management and will be a strong addition to Adherium as an enterprise leader. Anne’s appointment marks an important step as we further strengthen our corporate activities in Australia and follows the recent announcement of the investment being made in software and device development with Planet Innovation in Melbourne.”
Motion said, “I am delighted to take on the role of CEO for Adherium and lead the team to success as we execute our strategy which will deliver shareholder value and improve patients’ lives. This is an exciting time for Adherium given the increased focus on telehealth coming alongside reimbursement for remote patient monitoring now in place in the USA. Adherium has a new team implementing a focused, market relevant, provider value driven strategy and a clear development roadmap to re-establish market leadership in inhaled medication device coverage including physiological data reporting. The business is already making great progress as seen in our recent partnering announcement with HGE and we look forward to providing further promising newsflow.”
Read the Adherium press release.
